ID   JHOC-9
AC   CVCL_4643
SY   JHOC9
DR   CLO; CLO_0051447
DR   BioSample; SAMN03472024
DR   cancercelllines; CVCL_4643
DR   Cosmic; 1708380
DR   Cosmic; 2582796
DR   GEO; GSM1176279
DR   GEO; GSM2474977
DR   Progenetix; CVCL_4643
DR   RCB; RCB2226
DR   Wikidata; Q54898652
RX   PubMed=22705003;
RX   PubMed=24023729;
RX   PubMed=25846456;
RX   PubMed=25960936;
RX   PubMed=28273451;
CC   Population: Japanese.
CC   HLA typing: A*24:02,11:01; B*35:08,40:01; C*07:02,04:01; DRB1*08:01,08:01 (PubMed=25960936).
CC   Sequence variation: Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Unspecified (PubMed=22705003; PubMed=25846456; PubMed=28273451).
CC   Omics: Transcriptomics; RNAseq.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
ST   Source(s): RCB=RCB2226
ST   Amelogenin: X
ST   CSF1PO: 10,13
ST   D13S317: 10
ST   D16S539: 12
ST   D5S818: 10
ST   D7S820: 8,12
ST   TH01: 6,9
ST   TPOX: 8,11
ST   vWA: 17
DI   NCIt; C40078; Ovarian clear cell adenocarcinoma
DI   ORDO; Orphanet_398971; Clear cell adenocarcinoma of the ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   34Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 26
//
RX   PubMed=22705003; DOI=10.1016/j.humpath.2012.03.011;
RA   Rahman M., Nakayama K., Rahman M.T., Nakayama N., Ishikawa M.,
RA   Katagiri A., Iida K., Nakayama S., Otsuki Y., Shih I.-M.,
RA   Miyazaki K.;
RT   "Clinicopathologic and biological analysis of PIK3CA mutation in
RT   ovarian clear cell carcinoma.";
RL   Hum. Pathol. 43:2197-2206(2012).
//
RX   PubMed=24023729; DOI=10.1371/journal.pone.0072162; PMCID=PMC3762837;
RA   Anglesio M.S., Wiegand K.C., Melnyk N., Chow C., Salamanca C.M.,
RA   Prentice L.M., Senz J., Yang W., Spillman M.A., Cochrane D.R.,
RA   Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.;
RT   "Type-specific cell line models for type-specific ovarian cancer
RT   research.";
RL   PLoS ONE 8:e72162.1-e72162.13(2013).
//
RX   PubMed=25846456; DOI=10.3892/ijo.2015.2951;
RA   Takenaka M., Saito M., Iwakawa R., Yanaihara N., Saito M., Kato M.,
RA   Ichikawa H., Shibata T., Yokota J., Okamoto A., Kohno T.;
RT   "Profiling of actionable gene alterations in ovarian cancer by
RT   targeted deep sequencing.";
RL   Int. J. Oncol. 46:2389-2398(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028;
RA   Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J.,
RA   Paterson J., Sircoulomb F., Krzyzanowski P.M., Novak M., Doodnauth S.A.,
RA   Suarez Saiz F.J., Cullis J., Al-awar R., Neel B.G., McPherson J.,
RA   Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.;
RT   "Interrogation of functional cell-surface markers identifies CD151
RT   dependency in high-grade serous ovarian cancer.";
RL   Cell Rep. 18:2343-2358(2017).
//